期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血液恶性肿瘤靶向治疗10年进展

原文传递
导出
摘要 十年来，我们的生活水平有了突飞猛进的变化，其中科学技术的应用更是让人们的生活变得高效便捷。同样，在血液恶性肿瘤的治疗领域，随着医学研究的深入，也带来了巨大的改变，其中靶向治疗的开展，大大改善了一部分患者的治疗效果和预后。以下就血液恶性肿瘤该方面的进展谈谈个人的看法。
作者 王黎 沈志祥
机构地区 上海交通大学医学院附属瑞金医院血液科
出处 《中华内科杂志》 CAS CSCD 北大核心 2013年第2期121-123,共3页 Chinese Journal of Internal Medicine
关键词 血液恶性肿瘤 靶向治疗 科学技术 医学研究 治疗效果 生活水
分类号 R733 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Chen SJ, Zhou GB, Zhang XW, et al. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 2011,117 : 6425- 6437.
  • 2Zhang XW, Yan X J, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 2010,328:240-243.
  • 3Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As203 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 2004,101:5328-5335.
  • 4Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all- trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 2009,106:3342-3347.
  • 5Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng! J Med, 2006,355:2408-2417.
  • 6Kantarjian HM, Giles F, Gattermann 5/, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood ,2007,110:3540-3546.
  • 7Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 2007,109:4143-4150.
  • 8L Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood, 2012, 119: 3403 -3412.
  • 9ho K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature, 2008, 453 : 1072- 1078.
  • 10Yin T, Wu YL, Sun HP, et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood, 2004,104:4219-4225.

二级参考文献21

  • 1Wang ZY, Chen Z. Acute promyelocytie leukemia: from highly fatal to highly curable. Blood, 2008,11 1 :2505-2515.
  • 2Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood, 2002,99:3136-3143.
  • 3Donnel MRO, Abboud CN, Altman J, et al. The NCCN clinical practice guidelines in oncology (NCCN Guidelines TM ) acute myelogenous leukemia [ R/OL 1. [ 2001--04-10 ]. http://www. nccn. org/profession/s/physician g|s/pdf/cm|, pdf.
  • 4Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program, 2009, 2009 : 385-395.
  • 5Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol Educ Program, 2010, 2010:47-55.
  • 6Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell, 2010,17 : 13-27.
  • 7Deininger M, O' Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up : sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. 51st ASH Annual Meeting and Exposition Abstracts, New Orleans, US, 2008. New Orleans: American Society of Hematology ,2008 : 186.
  • 8Avvisati G, Petti MC, Lo-Coeo F, et al. Induction therapy with idarubiein alone significantly influences event-free survival duration in patients with newly diagnosed hypergranuIar acute promyeloeytie leukemia: final results of the GIMEiVIA randomized study LAP 0389 with 7 years of minimal follow-up. Blood, 2002, 100:3141-3146.
  • 9Jiag Q, Xu LP, Liu DH, et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood, 2011,117:3032-3040.
  • 10Santos FP, Verstovsek S. JAK2 inhibitors: what's the true therapeutic potential? Blood Rev, 2011,25:53-63.

共引文献2

中华内科杂志
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部